ISI Reiterates Buy, $120 PT On Biogen
International Strategy & Investment Group (ISI) reiterated a buy rating and $120 price target on biotech firm Biogen Idec (Nasdaq: BIIB) today. The price target implies only limited upside for the stock. The stock is up half a percent today.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.